Singapore markets closed

Adicet Bio, Inc. (ACET)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.3500-0.1000 (-6.90%)
At close: 04:00PM EDT
1.3700 +0.02 (+1.48%)
After hours: 07:40PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.4500
Open1.4600
Bid1.3000 x 200
Ask1.3600 x 200
Day's range1.3400 - 1.4800
52-week range1.1000 - 4.8100
Volume491,315
Avg. volume1,058,769
Market cap110.934M
Beta (5Y monthly)1.73
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Business Wire

    Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

    REDWOOD CITY, Calif. & BOSTON, June 05, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potential treatment of relapsed/refractory class III or class IV lupus nephritis.

  • Business Wire

    Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    REDWOOD CITY, Calif. & BOSTON, May 31, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on May 31, 2024.

  • Business Wire

    Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference

    REDWOOD CITY, Calif. & BOSTON, May 29, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference being held from June 5-6, 2024 in New York.